Clinical trial
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced…
NCT00014456 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00014456 |
|---|---|
| Title | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors |
| Official title | A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer and 2 more |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel, gemcitabine hydrochloride |
| Enrollment | 35 |
| Start date | Mar 1, 2000 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: